Jennison Associates’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Jennison Associates’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-413,565	Closed	-$15.4M	–	749
2021 Q2	$15.4M	Hold	413,565	–	–	0.01%	410
2021 Q1	$10.6M	Buy	+413,565	New	+$10.6M	0.01%	421
2020 Q3	–	Sell	-21,143	Closed	-$537K	–	706
2020 Q2	$537K	Buy	+21,143	New	+$455K	﹤0.01%	587

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Jennison Associates's DRNA Position: Q3 2021 in Review

Jennison Associates sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 413,565 shares — an estimated $15.4M sold.

Jennison Associates first reported a position in DRNA in Q2 2020 and held it in 3 quarters. The position peaked at $15.4M in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Jennison Associates reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Jennison Associates sold 413,565 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $15.4M.
Jennison Associates first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 3 quarters.
Jennison Associates's Dicerna Pharmaceuticals, Inc. position peaked at $15.4M in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Jennison Associates's 13F filing for Q3 2021, filed 9 Nov 2021.